|
|
|
OS
p value
|
|
DFS
p value
|
Age (years) (mean ± SD)
|
57.6 ± 11.4 |
57.6 ± 11.4 |
0.752 |
|
0.094 |
Age (years), n (%)
> 60
< 60
|
13 (39.4%)
20 (60.6%)
|
13 (39.4%)
20 (60.6%)
|
0.977
|
|
0.370
|
Gender, n (%)
Female
Male
|
11 (33.3%)
22 (66.7%)
|
11 (33.3%)
22 (66.7%)
|
0.859
|
|
0.151
|
BMI (kg/m2) (mean ± SD)
|
27.6 ± 4.1 |
27.6 ±
4.1 |
0.379 |
|
0.317 |
Smoking, n (%)
Yes
No
|
20 (60.6%)
13 (39.4%)
|
20 (60.6%)
13 (39.4%)
|
0.083
|
|
0.547
|
Smoking (pack years) (mean ± SD)
|
39.5 ± 19.1 |
39.5 ± 19.1 |
|
|
|
Alcohol intake, n (%)
Yes
No
|
3 (9.1%)
30 (90.9%)
|
3 (9.1%)
30 (90.9%)
|
0.612
|
|
0.148
|
Symptoms, n (%)
Flank pain
Hematuria
Abdominal swelling
Weight loss
Incidental
|
14 (42.4%)
11 (33.3%)
4 (12.1%)
1 (3.1%)
3 (9.1%)
|
14 (42.4%)
11 (33.3%)
4 (12.1%)
1 (3.1%)
3 (9.1%)
|
0.709
|
|
0.504
|
CCI, n (%)
0
1
2
3
|
8 (24.2%)
15 (45.4%)
9 (27.2%)
1 (3.2%)
|
8 (24.2%)
15 (45.4%)
9 (27.2%)
1 (3.2%)
|
0.147
|
|
0.538
|
Anticoagulant - antiplatelet medication, n (%)
Yes
No
|
5 (15.1%)
28 (84.9%)
|
5 (15.1%)
28 (84.9%)
|
0.413
|
|
0.264
|
ASA score, n (%)
ASA I
ASA II
ASA III
|
15 (45.4%)
16 (48.5%)
2 (6.1%)
|
15 (45.4%)
16 (48.5%)
2 (6.1%)
|
0.362
|
|
0.615
|
ECOG score, n (%)
ECOG 0
ECOG 1
|
27 (81.9%)
6 (18.1%)
|
27 (81.9%)
6 (18.1%)
|
0.082
|
|
0.776
|
Familial cancer history, n (%)
Yes
No
|
6 (18.1%)
27 (81.9%)
|
6 (18.1%)
27 (81.9%)
|
0.495
|
|
0.202
|
Tumor side, n (%)
Left kidney
Right kidney
|
10 (30.3%)
23 (69.7%)
|
10 (30.3%)
23 (69.7%)
|
0.717
|
|
0.392
|
Clinical tumor size (cm)
mean ± SD
|
10.7 ± 4.38
|
10.7 ± 4.38
|
|
|
|
Clinical tumor size (cm), n (%)
≤4 cm
>4, ≤ 7 cm
>7, ≤ 10 cm
>10 cm
|
0
8 (24.2%)
11 (33.3%)
14 (42.4%)
|
0
8 (24.2%)
11 (33.3%)
14 (42.4%)
|
0.047
|
|
0.249
|
Mayo Clinic thrombus level, n (%)
Level I
Level II
Level III
Level IV
|
15 (45.4%)
5 (15.2%)
8 (24.2%)
5 (15.2%)
|
15 (45.4%)
5 (15.2%)
8 (24.2%)
5 (15.2%)
|
0.057
|
|
0.02
|
Clinical stage, n (%)
T3a
T3b
T3c
T4
|
9 (27.2%)
16 (48.5%)
8 (24.2%)
0
|
9 (27.2%)
16 (48.5%)
8 (24.2%)
0
|
0.473
|
|
0.294
|
Preoperative clinical M1 disease, n (%)
Yes
No
|
9 (27.2%)
24 (72.8%)
|
9 (27.2%)
24 (72.8%)
|
0.014
|
|
-
|
Preoperative clinical N1 disease, n (%)
Yes
No
|
8 (24.2%)
25 (75.8%)
|
8 (24.2%)
25 (75.8%)
|
0.973
|
|
-
|
(b) |
|
|
|
|
|
Operation type, n (%)
Open radical nephrectomy
Laparoscopic radical nephrectomy
Open nephroureterectomy
|
31 (93.8%)
1 (3.1%)
1 (3.1%)
|
31 (93.8%)
1 (3.1%)
1 (3.1%)
|
0.998
|
|
0.1
|
Additional procedure, n (%)
Thrombectomy
LND
CABG
Intracardiac tumor excision
Valvuloplasty
Sternotomy
Metastasectomy
Cholecystectomy
Hepatic lobectomy
|
33 (100%)
21 (63.6%)
3 (9.1%)
3 (9.1%)
3 (9.1%)
8 (24.2%)
1 (3.1%)
2 (6.2%)
1 (3.1%)
|
33 (100%)
21 (63.6%)
3 (9.1%)
3 (9.1%)
3 (9.1%)
8 (24.2%)
1 (3.1%)
2 (6.2%)
1 (3.1%)
|
|
|
|
Mean blood loss (cc) (mean ± SD)
|
1064.8 ± 1288.97 |
1064.8 ± 1288.97 |
0.763 |
|
0.819 |
Operative time (min) (mean ± SD)
|
264.5 ± 91.8 |
264.5
± 91.8 |
0.191 |
|
0.370 |
Mean transfusion, per patient (mean ± SD)
ES
FFP
|
1.8
1.5
|
1.8
1.5
|
0.248
|
|
0.328
|
Perioperative complication, n (%)
Hemorrhage
|
3 (9.1%)
|
3 (9.1%)
|
0.451
|
|
0.378
|
Postoperative early complication, n (%)
Infection
Hemorrhage
|
7 (21.2%)
4 (12.1%)
|
7 (21.2%)
4 (12.1%)
|
0.217
|
|
0.285
|
Clavien score, n (%)
Clavien I
Clavien II
Clavien IIIa
Clavien IIIb
Clavien IV
Clavien V
|
11 (33.2%)
19 (57.5%)
1 (3.1%)
2 (6.2%)
0
0
|
11 (33.2%)
19 (57.5%)
1 (3.1%)
2 (6.2%)
0
0
|
0.184
|
|
0.122
|
(c) |
(c) |
(c) |
(c) |
(c) |
(c) |
Histopathology, n (%)
RCC
Invasive urothelial carcinoma
Mesenchymal malignant tumor
PTEN-Ewing group sarcoma
|
Histopathology, n (%)
RCC
Invasive urothelial carcinoma
Mesenchymal malignant tumor
PTEN-Ewing group sarcoma
|
30 (90.7%)
1 (3.1%)
1 (3.1%)
1 (3.1%)
|
0.224
|
|
0.311
|
RCC, subtypes, n (%)
Clear cell RCC
Chromophobe RCC
Papillary RCC
Conventional RCC
Unclassified
|
RCC, subtypes, n (%)
Clear cell RCC
Chromophobe RCC
Papillary RCC
Conventional RCC
Unclassified
|
19 (63.4%)
2 (6.7%)
1 (3.3%)
3 (9.9%)
5 (16.7%)
|
0.873
|
|
0.805
|
Sarcomatoid differentiation, n (%)
Yes
No
|
Sarcomatoid differentiation, n (%)
Yes
No
|
8 (24.2%)
25 (75.8%)
|
0.810
|
|
0.283
|
Histological pattern, n (%)
Solid
Solid, alveolar
Solid, tubular
Solid, trabecular
Tubular, microcystic
Tubular, tubulopapillar
Alveolar, fascicular
Invasive
|
Histological pattern, n (%)
Solid
Solid, alveolar
Solid, tubular
Solid, trabecular
Tubular, microcystic
Tubular, tubulopapillar
Alveolar, fascicular
Invasive
|
11 (33.3%)
11 (33.3%)
4 (12.2%)
2 (6.1%)
2 (6.1%)
1 (3.0%)
1 (3.0%)
1 (3.0%)
|
0.210
|
|
0.053
|
Pathological cancer size (cm) (mean ± SD)
Mean
|
Pathological cancer size (cm) (mean ± SD)
Mean
|
10.9 ± 4.9
|
|
|
|
Pathological cancer size (cm), n (%)
≤4
>4, ≤ 7
>7, ≤ 10
>10
|
Pathological cancer size (cm), n (%)
≤4
>4, ≤ 7
>7, ≤ 10
>10
|
0
5 (15.2%)
16 (48.5%)
12 (36.3%)
|
0.046
|
|
0.005
|
Fuhrman grade, n (%)
Grade I
Grade II
Grade III
Grade IV
|
Fuhrman grade, n (%)
Grade I
Grade II
Grade III
Grade IV
|
0
2 (7.4%)
12 (44.4%)
13 (48.2%)
|
0.750
|
|
0.260
|
Surgical margin, n (%)
Negative
Positive
|
Surgical margin, n (%)
Negative
Positive
|
32 (96.9%)
1 (3.1%)
|
0.591
|
|
0.935
|
Vascular invasion, n (%)
Yes
No
|
Vascular invasion, n (%)
Yes
No
|
30 (90.9%)
3 (9.1%)
|
0.562
|
|
0.252
|
Capsule and perinephric tissue invasion, n (%)
Yes
No
|
Capsule and perinephric tissue invasion, n (%)
Yes
No
|
18 (54.5%)
15 (45.5%)
|
0.506
|
|
0.163
|
Lymph node invasion, n (%)
Yes
No
|
Lymph node invasion, n (%)
Yes
No
|
11 (33.3%)
22 (66.7%)
|
0.066
|
|
0.437
|
OS = overall survival; DFS = disease-free survival; BMI = body mass
index; CCI = Charlson comorbidity index; ASA = American Society of
Anesthesiologists; ECOG = Eastern Cooperative Oncology Group; SD =
standard deviation; LND = lymph node dissection; CABG = coronary artery
bypass graft; ES = erythrocytes suspension; FFP = fresh frozen plasma;
RCC = renal cell carcinoma; PTEN = phosphatase and tensin homolog. |
OS
= overall survival; DFS = disease-free survival; BMI = body mass index;
CCI = Charlson comorbidity index; ASA = American Society of
Anesthesiologists; ECOG = Eastern Cooperative Oncology Group; SD =
standard deviation; LND = lymph node dissection; CABG = coronary artery
bypass graft; ES = erythrocytes suspension; FFP = fresh frozen plasma;
RCC = renal cell carcinoma; PTEN = phosphatase and tensin homolog. |
OS
= overall survival; DFS = disease-free survival; BMI = body mass index;
CCI = Charlson comorbidity index; ASA = American Society of
Anesthesiologists; ECOG = Eastern Cooperative Oncology Group; SD =
standard deviation; LND = lymph node dissection; CABG = coronary artery
bypass graft; ES = erythrocytes suspension; FFP = fresh frozen plasma;
RCC = renal cell carcinoma; PTEN = phosphatase and tensin homolog. |
OS
= overall survival; DFS = disease-free survival; BMI = body mass index;
CCI = Charlson comorbidity index; ASA = American Society of
Anesthesiologists; ECOG = Eastern Cooperative Oncology Group; SD =
standard deviation; LND = lymph node dissection; CABG = coronary artery
bypass graft; ES = erythrocytes suspension; FFP = fresh frozen plasma;
RCC = renal cell carcinoma; PTEN = phosphatase and tensin homolog. |
OS
= overall survival; DFS = disease-free survival; BMI = body mass index;
CCI = Charlson comorbidity index; ASA = American Society of
Anesthesiologists; ECOG = Eastern Cooperative Oncology Group; SD =
standard deviation; LND = lymph node dissection; CABG = coronary artery
bypass graft; ES = erythrocytes suspension; FFP = fresh frozen plasma;
RCC = renal cell carcinoma; PTEN = phosphatase and tensin homolog. |
OS
= overall survival; DFS = disease-free survival; BMI = body mass index;
CCI = Charlson comorbidity index; ASA = American Society of
Anesthesiologists; ECOG = Eastern Cooperative Oncology Group; SD =
standard deviation; LND = lymph node dissection; CABG = coronary artery
bypass graft; ES = erythrocytes suspension; FFP = fresh frozen plasma;
RCC = renal cell carcinoma; PTEN = phosphatase and tensin
homolog. |